ALUMIS
Alumis provides precision medicines. They transform the lives of patients with autoimmune diseases. They bring a proven track record in precision drug development of groundbreaking therapies. They rewrite the autoimmune treatment playbook with a unique precision analytics platform to advancing their understanding of immunologic diseases. They build a pipeline of therapeutics based on genetically validated targets for application in the treatment of multiple autoimmune disease indications.
ALUMIS
Industry:
Biotechnology Health Care Medical Precision Medicine
Founded:
2021-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.alumis.com
Total Employee:
11+
Status:
Active
Contact:
+1 650 231 6625
Email Addresses:
[email protected]
Similar Organizations
BlueRock Therapeutics
It is a regenerative medicine company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
CycloPure
CycloPure is a materials science company
GENE.AC
GENE.AC is a provider of domestic precision medicine solutions.
Gene Predictis
Gene Predictis is a Swiss precision medicine company.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Renerva
Renerva is a rapidly-growing and innovative medical device company.
Saol Therapeutics
Saol Therapeutics is a biotech pharmaceutical company.
Stabiliz Orthopaedics
Stabiliz Orthopaedics develops novel enhancements for orthopedic medical devices using FDA-approved technologies.
ENU Nutrition
ENU Nutrition develops and commercializes nutritional products.
Current Employees Featured
Official Site Inspections
http://www.alumis.com
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Alumis"
The leadership team and Board of Directors at Alumis Inc.
Martin Babler is the President, Chief Executive Officer and Chairman of the Board at Alumis, Inc. Prior to Alumis, he served as President and CEO of Principia Biopharma, until its acquisition …See details»
Alumis - Crunchbase Company Profile & Funding
Organization. Alumis . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Alumis is a precision medicines …See details»
Alumis Inc. is focused on immune-mediated disease therapies
At Alumis, we are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases. Rooted in an unwavering commitment to deepen …See details»
Alumis - Crunchbase Company Profile & Funding
Organization. Alumis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Alumis is a precision …See details»
Investor Relations | Alumis Inc.
Nov 4, 2024 Alumis Inc. 280 East Grand Avenue South San Francisco CA 94080 (650) 231-6625See details»
Alumis Company Profile 2024: Stock Performance
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages …See details»
Esker Therapeutics Announces Name Change to Alumis …
Jan 6, 2022 The company’s name change to Alumis (“alumer” for “lighten/enlightened” and “immunis” for “immunology”) is reflective of the transformation of the organization and overall vision ...See details»
Alumis Inc. (ALMS) Company Profile & Overview
Jun 28, 2024 Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor …See details»
Alumis - Funding, Financials, Valuation & Investors - Crunchbase
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
Alumis Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Alumis (formerly known as Esker Therapeutics) is a clinical-stage biopharmaceutical company developing oral therapies. It specializes in the discovery, …See details»
Alumis Expands Industry-Leading Leadership Team With …
Apr 6, 2022 Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, …See details»
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Buy" by …
35 minutes ago Alumis has a 1-year low of $7.66 and a 1-year high of $13.53. Alumis Company Profile (Get Free Report. Our mission is to significantly improve the lives of patients by …See details»
Alumis - Contacts, Employees, Board Members, Advisors & Alumni …
Organization. Alumis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... About. Alumis has 5 current employee profiles, …See details»
Alumis Inc. (ALMS) Stock Price, News, Quote & History - Yahoo …
Find the latest Alumis Inc. (ALMS) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Careers, Values and Life at Alumis Inc.
At Alumis we have a deep dedication to transforming the lives of people suffering from immune-mediated diseases – we work hard to achieve this aspiration. We also believe in having fun, …See details»
Alumis Inc. (ALMS) Stock Price, Quote & News - Stock Analysis
6 days ago Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK …See details»
Our Approach at Alumis Inc.
Our Approach. At Alumis, our driving principle is to deliver the right medicine to achieve the best possible clinical outcome. To realize that goal, we are using our precision approach to …See details»
Alumis: A Best-In-Class TYK2 Inhibitor - Seeking Alpha
Nov 28, 2024 Summary. Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data …See details»
Why It Matters | Alumis Inc.
The first application of our precision approach is focused on tyrosine kinase 2 (TYK2), an enzyme (or protein) that is centrally involved in inflammation and autoimmune signaling pathways.We …See details»